151 related articles for article (PubMed ID: 36844257)
1. Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
Kurshan A; Snell LB; Prior L; Tam JCH; Graham C; Thangarajah R; Edgeworth JD; Nebbia G; Doores KJ
Oxf Open Immunol; 2023; 4(1):iqac012. PubMed ID: 36844257
[TBL] [Abstract][Full Text] [Related]
2. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
3. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
[TBL] [Abstract][Full Text] [Related]
4. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
[TBL] [Abstract][Full Text] [Related]
6. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
Nomura T; Kitagawa H; Kakimoto M; Kaiki Y; Nazmul T; Miyamori D; Omori K; Shigemoto N; Ito M; Sakaguchi T; Ohge H
J Infect Chemother; 2022 Jul; 28(7):912-917. PubMed ID: 35370078
[TBL] [Abstract][Full Text] [Related]
7. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
[TBL] [Abstract][Full Text] [Related]
8. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
[TBL] [Abstract][Full Text] [Related]
9. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV.
Sasaki H; Miyata N; Yoshimura Y; Tachikawa N
Infection; 2022 Jun; 50(3):771-774. PubMed ID: 35181864
[TBL] [Abstract][Full Text] [Related]
10. Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.
Haskologlu IC; Erdag E; Sayiner S; Abacioglu N; Sehirli AO
Mol Biol Rep; 2022 May; 49(5):4061-4068. PubMed ID: 35389130
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
Arikawa S; Fukuoka K; Nakamoto K; Kunitomo R; Matsuno Y; Shimazaki T; Saraya T; Kawakami T; Kishimoto M; Komagata Y; Kurai D; Ishi H; Kaname S
Clin Exp Nephrol; 2022 May; 26(5):476-485. PubMed ID: 35182277
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
Manali M; Bissett LA; Amat JAR; Logan N; Scott S; Hughes EC; Harvey WT; Orton R; Thomson EC; Gunson RN; Viana M; Willett B; Murcia PR
J Infect Dis; 2022 Dec; 227(1):40-49. PubMed ID: 35920058
[TBL] [Abstract][Full Text] [Related]
13. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity.
Nguyen H; Salkeld J; Agarwal S; Goodman A
Clin Infect Pract; 2021 Nov; 12():100089. PubMed ID: 34426799
[TBL] [Abstract][Full Text] [Related]
14. Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment.
Thümmler L; Konik M; Lindemann M; Fisenkci N; Koldehoff M; Gäckler A; Horn PA; Theodoropoulos F; Taube C; Zettler M; Anastasiou OE; Braß P; Jansen S; Witzke O; Rohn H; Krawczyk A
Front Immunol; 2022; 13():980698. PubMed ID: 36311723
[TBL] [Abstract][Full Text] [Related]
15. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
[TBL] [Abstract][Full Text] [Related]
16. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
17. Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant.
Dimeglio C; Herin F; Da-Silva I; Gernigon C; Porcheron M; Chapuy-Regaud S; Izopet J
Microbiol Spectr; 2022 Aug; 10(4):e0270621. PubMed ID: 35867411
[TBL] [Abstract][Full Text] [Related]
18. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ
mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
20. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Toledo EG; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RK; Rannard S; Stewart J; Owen A
bioRxiv; 2023 Mar; ():. PubMed ID: 35118468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
